UNSPSC 51341804: Oseltamivir carboxylate

This classification denotes an antiviral agent with the molecular formula C14H24N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K6106LV5Q8, chemically known as oseltamivir acid, (-)-, but more generally known as oseltamivir carboxylate, which bears US NIH Compound Identifier 449381. European Medicines Agency schedules oseltamivir carboxylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03553MIG. Most nations, for tariff purposes, schedule oseltamivir carboxylate under HS 29242995.

SMILES: CCC(CC)O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)O.

UNSPSC 51341804 Oseltamivir carboxylate is a Commodity code representing a specific antiviral pharmaceutical, yet recent state and local solicitations tagged to this code do not reflect procurement of oseltamivir itself. Instead, the code appears in opportunities for broader pharmaceutical and medical supply acquisition—generic multi-source drugs, over-the-counter products, naloxone, and direct-to-manufacturer prescription programs. The mismatch between the code's nominal scope and actual buying activity signals either misclassification in the source records or a state and local taxonomy application that does not segment pharmaceutical procurement as finely as UNSPSC design intends. State and local buyers soliciting under this code include health and human services departments (Texas Health and Human Services Commission), cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple state and local members), county public health bodies (Seminole County, Florida), and city fire departments (City of Tampa). The work being bought spans pharmaceutical manufacturing supply agreements, emergency medical supplies for rescue divisions, naloxone procurement for community health initiatives, and exploratory vendor capability assessments for direct-to-manufacturer prescription fulfillment.

Geographic activity in the most recent opportunities centers on Florida, Texas, Minnesota, and Oregon. Representative recent solicitations include the Texas Health and Human Services Commission's Request for Information HHS0017013 (posted April 3, 2026) seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, the City of Tampa's IFB 26P00145 (due March 13, 2026) for medical and first aid supplies for the Tampa Fire Department Rescue Division with an estimated contract amount of $700,000.00 and a 5% bid discount set-aside for certified Small Local Business Enterprises, and Seminole County's IFB 60459723LAS (due July 26, 2023) for naloxone and safe drug deactivation systems with annual quantities of 1,900 units of naloxone and 800 deactivation systems delivered quarterly to the Seminole County Community Health Building. No opportunities under this code are currently active with imminent response deadlines.